219 related articles for article (PubMed ID: 11702307)
1. Denileukin diftitox.
Figgitt DP; Lamb HM; Goa KL
Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
[TBL] [Abstract][Full Text] [Related]
2. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
[TBL] [Abstract][Full Text] [Related]
3. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
[TBL] [Abstract][Full Text] [Related]
4. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
Olsen E; Duvic M; Frankel A; Kim Y; Martin A; Vonderheid E; Jegasothy B; Wood G; Gordon M; Heald P; Oseroff A; Pinter-Brown L; Bowen G; Kuzel T; Fivenson D; Foss F; Glode M; Molina A; Knobler E; Stewart S; Cooper K; Stevens S; Craig F; Reuben J; Bacha P; Nichols J
J Clin Oncol; 2001 Jan; 19(2):376-88. PubMed ID: 11208829
[TBL] [Abstract][Full Text] [Related]
5. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
Chin KM; Foss FM
Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
[TBL] [Abstract][Full Text] [Related]
6. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication.
Foss FM; Bacha P; Osann KE; Demierre MF; Bell T; Kuzel T
Clin Lymphoma; 2001 Mar; 1(4):298-302. PubMed ID: 11707845
[TBL] [Abstract][Full Text] [Related]
7. Denileukin diftitox.
Saxon M
Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL.
Kadin ME; Vonderheid EC
Nat Rev Clin Oncol; 2010 Aug; 7(8):430-2. PubMed ID: 20668480
[No Abstract] [Full Text] [Related]
9. Optimizing denileukin diftitox (Ontak) therapy.
Duvic M; Talpur R
Future Oncol; 2008 Aug; 4(4):457-69. PubMed ID: 18684057
[TBL] [Abstract][Full Text] [Related]
10. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
[TBL] [Abstract][Full Text] [Related]
11. Denileukin diftitox as novel targeted therapy for lymphoid malignancies.
Wong BY; Gregory SA; Dang NH
Cancer Invest; 2007 Sep; 25(6):495-501. PubMed ID: 17882663
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with denileukin diftitox (ONTAK).
Foss F
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S11-6. PubMed ID: 16516670
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
Talpur R; Duvic M
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
[TBL] [Abstract][Full Text] [Related]
14. Denileukin diftitox for the treatment of panniculitic lymphoma.
McGinnis KS; Shapiro M; Junkins-Hopkins JM; Smith M; Lessin SR; Vittorio CC; Rook AH
Arch Dermatol; 2002 Jun; 138(6):740-2. PubMed ID: 12056952
[No Abstract] [Full Text] [Related]
15. Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis.
Avarbock AB; Loren AW; Park JY; Junkins-Hopkins JM; Choi J; Litzky LA; Rook AH
Am J Hematol; 2008 Jul; 83(7):593-5. PubMed ID: 18335564
[TBL] [Abstract][Full Text] [Related]
16. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
Attia P; Maker AV; Haworth LR; Rogers-Freezer L; Rosenberg SA
J Immunother; 2005; 28(6):582-92. PubMed ID: 16224276
[TBL] [Abstract][Full Text] [Related]
17. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.
Foss F; Demierre MF; DiVenuti G
Blood; 2005 Jul; 106(2):454-7. PubMed ID: 15811959
[TBL] [Abstract][Full Text] [Related]
18. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.
Knueppel A; Lange S; Altmann S; Sekora A; Knuebel G; Vogel H; Lindner I; Freund M; Junghanss C
Vet Immunol Immunopathol; 2012 Jan; 145(1-2):233-40. PubMed ID: 22173275
[TBL] [Abstract][Full Text] [Related]
19. [Preclinical and clinical researches of Denileukin Diftitox (Genetical Recombination) (Remitoro
Shiiba H; Takechi A; Asakura S; Kawaguchi T; Sato M
Nihon Yakurigaku Zasshi; 2022; 157(5):376-382. PubMed ID: 36047157
[TBL] [Abstract][Full Text] [Related]
20. Denileukin diftitox: a concise clinical review.
Eklund JW; Kuzel TM
Expert Rev Anticancer Ther; 2005 Feb; 5(1):33-8. PubMed ID: 15757436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
